While treatment options had traditionally been limited, the approval of eculizumab in 2007 changed the management of PNH dramatically as the blockage of C5 activation and MAC formation largely impaired hemolysis. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.